QTc interval prolongation by d-propoxyphene: What about other analgesics?

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1397-1409

  Raffa, Robert B ^a   Burmeister, Jeffrey J ^a   Yuvasheva, Ekaterina ^a   Pergolizzi, Joseph V ^a,b,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; HERG; Non opioids; Opioids; QT interval

Indexed keywords

17 METHYLNALTREXONE; ALFENTANIL; ALVIMOPAN; ANALGESIC AGENT; BUPRENORPHINE; BUTORPHANOL; CODEINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVO ACETYLMETHADOL; METHADONE; NALBUPHINE; NALOXONE; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; OXYMORPHONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; SUFENTANIL; TAPENTADOL; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ELECTROCARDIOGRAM; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; QT INTERVAL; QT PROLONGATION; REVIEW; STRUCTURE ACTIVITY RELATION; TORSADE DES POINTES;

EID: 84863098538     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.682150     Document Type: Review

References (106)

1. Xiao Y, Smith RD, Caruso FS, Kellar KJ. Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther 2001;299(1):366-71
2. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274(3):1263-70
3. Due SL, Sullivan HR, McMahon RE. Propoxyphene: pathways of metabolism in man and laboratory animals. Biomed Mass Spectrom 1976;3(5):217-25
4. Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997;315(7122):1565-71
5. Sandilands EA, Bateman DN. Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol 2008;66(2):290-3
6. Hawton K, Bergen H, Simkin S, et al. Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: Time series analysis. BMJ 2009;338:b2270
7. Afshari R, Good AM, Maxwell SR, Bateman DN. Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics. Br J Clin Pharmacol 2005;60(4):444-7
8. Afshari R, Maxwell S, Dawson A, Bateman DN. ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning. Clin Toxicol (Phila) 2005;43(4):255-9
9. Bateman ND, Sandilands EA. European medicines evaluation agency bans dextropropoxyphene: A landmark decision for clinical toxicology? Clin Toxicol (Phila) 2009;47(8):782-3
10. FDA Drug Safety Communication: FDA recommends against the continued use of propoxyphene. Available from: http://www.fda/gov/Drugs/DrugSafety/ucm234338. htm [Last accessed 25 March 2012]
11. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163(22):2716-24
12. Macwilliam JA. Some applications of physiology to medicine: Ii.-ventricular fibrillation and sudden death. Br Med J 1923;2(3267):215-19
13. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966;59(2):263-72
14. Bazett HC. the time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol 1920;53(5): 320-39
15. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23
16. Fridericia LS. the duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica 1920;53:469-86
17. Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70(7):797-801
18. Dogan A, Tunc E, Varol E, et al. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann Noninvasive Electrocardiol 2005;10(2):134-41
19. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22
20. Sintra Grilo L, Carrupt P-A, Abriel H. Stereoselective inhibition of the hERG1 potassium channel. Front Pharmacol 2010;1:137
21. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167(22):2469-75
22. Schneider J, Hauser R, Andreas JO, et al. Differential effects of human ether-a-gogo-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol 2005;512(1):53-60
23. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45
24. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000;1(5):947-73
25. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002;5(1):116-26
26. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-gorelated gene K(+) currents. J Pharmacol Exp Ther 2002;303(2):688-94
27. Wang WX, Ebert SN, Liu XK, et al. Conventional antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 1998;32(1):123-8
28. Ekins S, Crumb WJ, Sarazan RD, et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002;301(2):427-34
29. Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357. pdf [Last accessed 25 March 2012]
30. Korpinen R, Saarnivaara L, Siren K. QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: Comparative effects of alfentanil and esmolol. Acta Anaesthesiol Scand 1995;39(6):809-13
31. Hiller A, Klemola UM, Saarnivaara L. Tracheal intubation after induction of anaesthesia with propofol, alfentanil and lidocaine without neuromuscular blocking drugs in children. Acta Anaesthesiol Scand 1993;37(8):725-9
32. Boachie-Ansah G, Sitsapesan R, Kane KA, Parratt JR. the antiarrhythmic and cardiac electrophysiological effects of buprenorphine. Br J Pharmacol 1989;97(3):801-8
33. Ilback NG, Siller M, Stalhandske T. Effects of buprenorphine on body temperature, locomotor activity and cardiovascular function when assessed by telemetric monitoring in rats. Lab Anim 2008;42(2):149-60
34. Martinez EA, Hartsfield SM, Melendez LD, et al. Cardiovascular effects of buprenorphine in anesthetized dogs. Am J Vet Res 1997;58(11):1280-4
35. Shafford HL, Schadt JC. Respiratory and cardiovascular effects of buprenorphine in conscious rabbits. Vet Anaesth Analg 2008;35(4):326-32
36. Esses JL, Rosman J, Do LT, et al. Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interv Card Electrophysiol 2008;23(2):117-19
37. Hanon S, Seewald RM, Yang F, et al. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 2010;28(1):19-22
38. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005;25(4):611-14
39. Baker JR, Best AM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006;40(3):392-6
40. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007;93(9):1051-5
41. Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: A mortality assessment study. Addiction 2009;104(6):993-9
42. Athanasos P, Farquharson AL, Compton P, et al. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis 2008;27(3):31-5
43. Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 2010;32(5):844-60
44. Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain 1997;1(3):185-90
45. Deisemann H, Ahrens N, Schlobohm I, et al. Effects of common antitussive drugs on the hERG potassium channel current. J Cardiovasc Pharmacol 2008;52(6):494-9
46. Kaplan B, Buchanan J, Krantz MJ. QTc prolongation due to dextromethorphan. Int J Cardiol 2011;148(3):363-4
47. Lindgren L, Saarnivaara L, Klemola UM. Protection by fentanyl against cardiac dysrhythmias during induction of anaesthesia. Eur J Anaesthesiol 1987;4(4):229-33
48. Chang DJ, Kweon TD, Nam SB, et al. Effects of fentanyl pretreatment on the QTc interval during propofol induction. Anaesthesia 2008;63(10):1056-60
49. Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician 2005;71(7):1353-8
50. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003(3):CD002208
51. Milroy CM, Forrest AR. Methadone deaths: A toxicological analysis. J Clin Pathol 2000;53(4):277-81
52. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14(11):747-53
53. Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep 2002;2(2):105-9
54. Chvilicek JP, Hurlbert BJ, Hill GE. Diuretic-induced hypokalaemia inducing torsades de pointes. Can J Anaesth 1995;42(12):1137-9
55. Cubeddu LX. QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. Am J Ther 2003;10(6):452-7
56. Gonzalez MM, Cavalcanti TC, Vianna CB, Timerman S. Hypomagnesaemia causing QT interval prolongation and torsade de pointes in an alcoholic patient. Resuscitation 2006;70(3):346-7
57. FDA Public Health Service. Death, narcotic overdose, and serious cardiac arrhythmias: Information for healthcare professionals on methadone. J Pain Palliat Care Pharmacother 2007;21(2):69-71
58. Lin C, Somberg T, Molnar J, Somberg J. the effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2009;113(1):59-65
59. Zunkler BJ, Wos-Maganga M. Comparison of the effects of methadone and heroin on human ether-a-go-gorelated gene channels. Cardiovasc Toxicol 2010;10(3):161-5
60. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81(5):719-28
61. Krantz MJ. Heterogeneous impact of methadone on the QTc interval: What are the practical implications? J Addict Dis 2008;27(4):5-9
62. Huh B, Park CH. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol 2010;58(4):338-43
63. Chugh SS, Socoteanu C, Reinier K, et al. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008;121(1):66-71
64. Wilcock A, Beattie JM. Prolonged QT interval and methadone: Implications for palliative care. Curr Opin Support Palliat Care 2009;3(4):252-7
65. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009;150(6):387-95
66. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105(3):499-506
67. Fanoe S, Jensen GB, Sjogren P, et al. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol 2009;67(2):172-9
68. Brasch H. Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations. Br J Pharmacol 1986;88(4):733-40
69. Oldroyd KG, Hicks MN, Cobbe SM. Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone. Cardiovasc Res 1993;27(2):296-303
70. Fagbemi O, Lepran I, Parratt JR, Szekeres L. Naloxone inhibits early arrhythmias resulting from acute coronary ligation. Br J Pharmacol 1982;76(4):504-6
71. Huang XD, Lee AY, Wong TM, et al. Naloxone inhibits arrhythmias induced by coronary artery occlusion and reperfusion in anaesthetized dogs. Br J Pharmacol 1986;87(3):475-7
72. Oldroyd KG, Rankin AC, Gray CE, et al. Failure to reproduce the in vitro cardiac electrophysiological effects of naloxone in humans. Br J Clin Pharmacol 1994;37(3):289-94
73. Markiewicz K, Kus W, Cholewa M, Bubinski R. Electrophysiologic effects of blocking and stimulating the opioid system in patients with unexplained heart palpitations. Clin Cardiol 1991;14(10):813-20
74. Herman BH, Asleson GS, Powell A, et al. Cardiovascular and other physical effects of acute administration of naltrexone in autistic children. J Child Adolesc Psychopharmacol 1993;3(3):157-68
75. Allhoff T, Renzing-Kohler K, Kienbaum P, et al. Electrocardiographic abnormalities during recovery from ultra-short opiate detoxification. Addict Biol 1999;4(3):337-44
76. Hajrasouliha AR, Tavakoli S, Jabehdar-Maralani P, et al. Cholestatic liver disease modulates susceptibility to ischemia/reperfusion-induced arrhythmia, but not necrosis and hemodynamic instability: The role of endogenous opioid peptides. J Hepatol 2005;43(3):491-8
77. Dzikiti TB, Stegmann GF, Hellebrekers LJ, et al. Sedative and cardiopulmonary effects of acepromazine, midazolam, butorphanol, acepromazine-butorphanol and midazolam-butorphanol on propofol anaesthesia in goats. J S Afr Vet Assoc 2009;80(1):10-16
78. Hofmeister EH, Mackey EB, Trim CM. Effect of butorphanol administration on cardiovascular parameters in isoflurane-anesthetized horses - a retrospective clinical evaluation. Vet Anaesth Analg 2008;35(1):38-44
79. Pircio AW, Buyniski JP, Roebel LE. Pharmacological effects of a combination of butorphanol and acetaminophen. Arch Int Pharmacodyn Ther 1978;235(1):116-23
80. Schneider J, Jahnel U, Linz K. Neutral effects of the novel analgesic tapentadol on cardiac repolarization due to mixed ion channel inhibitory activities. Drug Dev Res 2010;71(3):197-208
81. Oh C, Rengelshausen J, Mangold B, et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther 2010;48(10):678-87
82. Cho HC, Sohn JT, Park KE, et al. Inhibitory effect of tramadol on vasorelaxation mediated by ATP-sensitive K+ channels in rat aorta. Can J Anaesth 2007;54(6):453-60
83. Raimundo JM, Pontes LB, Antunes F, et al. Comparative effects of tramadol on vascular reactivity in normotensive and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008;35(10):1197-203
84. Musshoff F, Madea B. Fatality due to ingestion of tramadol alone. Forensic Sci Int 2001;116(2-3):197-9
85. Solarino B, Riesselmann B, Buschmann CT, Tsokos M. Multidrug poisoning involving nicotine and tramadol. Forensic Sci Int 2010;194(1-3):e17-19
86. Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol 1997;35(4):361-4
87. Sharma SS, Srinivasan SK, Krishnamoorthy S, et al. Preclinical safety pharmacological studies on the amorphous formulation of celecoxib. Arzneimittelforschung 2009;59(5):254-62
88. Pathak A, Boveda S, Defaye P, et al. Celecoxib-associated torsade de pointes. Ann Pharmacother 2002;36(7-8):1290-1
89. Brueggemann LI, Mackie AR, Martin JL, et al. Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. Mol Pharmacol 2011;79(1):10-23
90. Yang ZF, Wang HW, Zheng YQ, et al. Possible arrhythmiogenic mechanism produced by ibuprofen. Acta Pharmacol Sin 2008;29(4):421-9
91. Merrill GF, Merrill JH, Golfetti R, et al. Antiarrhythmic properties of acetaminophen in the dog. Exp Biol Med (Maywood) 2007;232(9):1245-52
92. Merrill GF, Goldberg E. Antioxidant properties of acetaminophen and cardioprotection. Basic Res Cardiol 2001;96(5):423-30
93. Xing J, Ma J, Zhang P, Fan X. Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652. Eur J Pharmacol 2010;630(1-3):1-9
94. Kenneback G, Bergfeldt L, Vallin H, et al. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121(5):1421-9
95. Kenneback G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther 1995;9(5):709-14
96. Iwahashi K. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change. Clin Neuropharmacol 1996;19(3):267-70
97. Dogan EA, Dogan U, Yildiz GU, et al. Evaluation of cardiac repolarization indices in well-controlled partial epilepsy: 12-Lead ECG findings. Epilepsy Res 2010;90(1-2):157-63
98. Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 2005;63(1):17-25
99. Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: A randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009;31(8):1776-86
100. Gonder JC, Gard EA, Lott NE III. Electrocardiograms of nine species of nonhuman primates sedated with ketamine. Am J Vet Res 1980;41(6):972-5
101. Inaba H, Hayami N, Ajiki K, et al. Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome. Circ J 2010;75(1):89-93
102. Alp R, Citil M, Uzun M, et al. Effects of therapeutic doses of Pregabalin on QTc interval in conscious rabbits. Eur Rev Med Pharmacol Sci 2008;12(4):223-8
103. Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006;109(1):116-17
104. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: A review of 235 consecutive cases. Br J Clin Pharmacol 2007;64(2):192-7
105. Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 2009;67(5):572-6
106. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007;22(3):129-33